303 related articles for article (PubMed ID: 30371278)
1. Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial.
White WB; Jalil F; Cushman WC; Bakris GL; Bergenstal R; Heller SR; Liu Y; Mehta C; Zannad F; Cannon CP
J Am Heart Assoc; 2018 Oct; 7(20):e009114. PubMed ID: 30371278
[TBL] [Abstract][Full Text] [Related]
2. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).
Cavender MA; White WB; Jarolim P; Bakris GL; Cushman WC; Kupfer S; Gao Q; Mehta CR; Zannad F; Cannon CP; Morrow DA
Circulation; 2017 May; 135(20):1911-1921. PubMed ID: 28246236
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial.
Sharma A; Vaduganathan M; Ferreira JP; Liu Y; Bakris GL; Cannon CP; White WB; Zannad F
J Am Heart Assoc; 2020 Jan; 9(1):e012797. PubMed ID: 31902327
[TBL] [Abstract][Full Text] [Related]
4. Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance.
Fleg JL; Evans GW; Margolis KL; Barzilay J; Basile JN; Bigger JT; Cutler JA; Grimm R; Pedley C; Peterson K; Pop-Busui R; Sperl-Hillen J; Cushman WC
Hypertension; 2016 Oct; 68(4):888-95. PubMed ID: 27504006
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
White WB; Wilson CA; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Heller SK; Mehta CR; Nissen SE; Zannad F; Kupfer S;
Hypertension; 2016 Sep; 68(3):606-13. PubMed ID: 27480840
[TBL] [Abstract][Full Text] [Related]
6. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Zannad F; Cannon CP; Cushman WC; Bakris GL; Menon V; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Lam H; White WB;
Lancet; 2015 May; 385(9982):2067-76. PubMed ID: 25765696
[TBL] [Abstract][Full Text] [Related]
7. On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults With Isolated Systolic Hypertension.
Yano Y; Rakugi H; Bakris GL; Lloyd-Jones DM; Oparil S; Saruta T; Shimada K; Matsuoka H; Imai Y; Ogihara T
Hypertension; 2017 Feb; 69(2):220-227. PubMed ID: 28049699
[TBL] [Abstract][Full Text] [Related]
8. Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.
Sharma A; Cannon CP; White WB; Liu Y; Bakris GL; Cushman WC; Zannad F
J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29769203
[TBL] [Abstract][Full Text] [Related]
9. High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.
Hwang YC; Morrow DA; Cannon CP; Liu Y; Bergenstal R; Heller S; Mehta C; Cushman W; Bakris GL; Zannad F; White WB
Diabetes Obes Metab; 2018 Mar; 20(3):654-659. PubMed ID: 29064626
[TBL] [Abstract][Full Text] [Related]
10. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
11. Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT.
Beddhu S; Chertow GM; Greene T; Whelton PK; Ambrosius WT; Cheung AK; Cutler J; Fine L; Boucher R; Wei G; Zhang C; Kramer H; Bress AP; Kimmel PL; Oparil S; Lewis CE; Rahman M; Cushman WC
J Am Heart Assoc; 2018 Sep; 7(18):e009326. PubMed ID: 30371182
[TBL] [Abstract][Full Text] [Related]
12. Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial.
Bergmark BA; Cannon CP; White WB; Jarolim P; Liu Y; Bonaca MP; Zannad F; Morrow DA
Diabetes Obes Metab; 2017 Jul; 19(7):962-969. PubMed ID: 28195387
[TBL] [Abstract][Full Text] [Related]
13. Intensive Blood Pressure Targets for Diabetic and Other High-Risk Populations: A Pooled Individual Patient Data Analysis.
Aggarwal R; Steinkamp J; Chiu N; Petrie B; Mirzan H
Hypertension; 2018 May; 71(5):833-839. PubMed ID: 29531175
[TBL] [Abstract][Full Text] [Related]
14. Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).
Pagidipati NJ; Navar AM; Pieper KS; Green JB; Bethel MA; Armstrong PW; Josse RG; McGuire DK; Lokhnygina Y; Cornel JH; Halvorsen S; Strandberg TE; Delibasi T; Holman RR; Peterson ED;
Circulation; 2017 Sep; 136(13):1193-1203. PubMed ID: 28626088
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
White WB; Kupfer S; Zannad F; Mehta CR; Wilson CA; Lei L; Bakris GL; Nissen SE; Cushman WC; Heller SR; Bergenstal RM; Fleck PR; Cannon CP;
Diabetes Care; 2016 Jul; 39(7):1267-73. PubMed ID: 27289121
[TBL] [Abstract][Full Text] [Related]
16. Association of Blood Pressure Measurements With Peripheral Artery Disease Events.
Itoga NK; Tawfik DS; Lee CK; Maruyama S; Leeper NJ; Chang TI
Circulation; 2018 Oct; 138(17):1805-1814. PubMed ID: 29930023
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).
Redon J; Mancia G; Sleight P; Schumacher H; Gao P; Pogue J; Fagard R; Verdecchia P; Weber M; Böhm M; Williams B; Yusoff K; Teo K; Yusuf S;
J Am Coll Cardiol; 2012 Jan; 59(1):74-83. PubMed ID: 22192672
[TBL] [Abstract][Full Text] [Related]
18. Assessing Optimal Blood Pressure in Patients With Asymptomatic Aortic Valve Stenosis: The Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS).
Nielsen OW; Sajadieh A; Sabbah M; Greve AM; Olsen MH; Boman K; Nienaber CA; Kesäniemi YA; Pedersen TR; Willenheimer R; Wachtell K
Circulation; 2016 Aug; 134(6):455-68. PubMed ID: 27486164
[TBL] [Abstract][Full Text] [Related]
19. Risk of Cardiovascular Disease and Chronic Kidney Disease According to 2017 Blood Pressure Categories in Diabetes Mellitus.
Kim YT; Chung HJ; Park BR; Kim YY; Lee JH; Kang DR; Kim JY; Lee MY; Lee JY
Hypertension; 2020 Sep; 76(3):766-775. PubMed ID: 32755407
[TBL] [Abstract][Full Text] [Related]
20. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).
Soliman EZ; Ambrosius WT; Cushman WC; Zhang ZM; Bates JT; Neyra JA; Carson TY; Tamariz L; Ghazi L; Cho ME; Shapiro BP; He J; Fine LJ; Lewis CE;
Circulation; 2017 Aug; 136(5):440-450. PubMed ID: 28512184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
